Exelixis | EXEL - Current Assets


Exelixis reported $1.21B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Takeda JPY 3.09T 25.94B Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026